CorMedix Seeks Shareholder Approval for Key Equity, Governance Changes

TL;DR

**CRMD is asking shareholders to greenlight a massive stock plan increase and preferred stock voting power, which smells like dilution and a power grab.**

AI Summary

CorMedix Inc. (CRMD) is holding a Special Meeting of Stockholders on November 10, 2025, to address five key proposals. The company seeks approval for the Exchange Cap Removal under Nasdaq Rule 5635(a), an amendment to the 2019 Omnibus Stock Incentive Plan to increase authorized shares by 4,312,000, and the ratification of previously adopted COD Amendments. Additionally, stockholders will vote on an amendment to the Certificate of Incorporation to grant preferred stockholders voting rights on certain charter amendments, and an Adjournment Proposal if insufficient votes are received. As of the September 23, 2025 record date, there were 78,340,257 shares of common stock outstanding, 89,623 shares of Series E preferred stock (representing 709,299 votes), and 2,000 shares of Series C-3 preferred stock (representing 2,000 votes) entitled to vote on specific proposals. The company is utilizing a 'Full Set Delivery' method for proxy materials, distributing paper copies and providing online access.

Why It Matters

This DEF 14A filing outlines critical governance and equity proposals that could significantly impact CorMedix's capital structure and executive compensation. Approving the 4,312,000 share increase for the 2019 Omnibus Stock Incentive Plan could lead to substantial dilution for existing common stockholders, while also providing more flexibility for employee incentives in a competitive biotech landscape. The proposed Certificate of Incorporation amendment granting preferred stockholders more voting power on charter changes could shift influence, particularly for major holders like affiliates of Elliott Associates, L.P., potentially affecting future strategic decisions and investor confidence. Investors need to weigh the benefits of incentivizing talent against potential dilution and governance shifts.

Risk Assessment

Risk Level: medium — The proposal to increase shares authorized for the 2019 Omnibus Stock Incentive Plan by 4,312,000 shares presents a significant dilution risk for existing common stockholders. Additionally, the Certificate of Incorporation Amendment Proposal could grant preferred stockholders, including affiliates of Elliott Associates, L.P., increased voting power on certain charter amendments, potentially altering governance dynamics.

Analyst Insight

Investors should carefully review the potential dilution from the 4,312,000 share increase for the incentive plan and the implications of enhanced preferred stockholder voting rights. Consider voting against proposals that could disproportionately dilute common equity or shift control without clear strategic benefits.

Key Numbers

• 4,312,000 — Additional shares for Incentive Plan (Represents potential dilution for common stockholders)
• 78,340,257 — Common shares outstanding (Baseline for voting power and dilution calculations)
• 89,623 — Series E preferred shares outstanding (Represents significant voting power (709,299 votes))
• 2,000 — Series C-3 preferred shares outstanding (Entitled to 2,000 votes on Proposal No. 3)
• November 10, 2025 — Special Meeting Date (Key date for shareholder decisions)
• September 23, 2025 — Record Date (Determines eligibility to vote at the Special Meeting)

Key Players & Entities

• CorMedix Inc. (company) — Registrant
• Nasdaq Rule 5635(a) (regulator) — Rule governing Exchange Cap Removal
• 4,312,000 shares (dollar_amount) — Increase in shares for 2019 Omnibus Stock Incentive Plan
• November 10, 2025 (date) — Date of Special Meeting of Stockholders
• September 23, 2025 (date) — Record date for voting eligibility
• 78,340,257 shares (dollar_amount) — Common stock outstanding as of record date
• 89,623 shares (dollar_amount) — Series E preferred stock outstanding as of record date
• 709,299 votes (dollar_amount) — Total votes from Series E preferred stock
• Elliott Associates, L.P. (company) — Affiliates hold Series E preferred stock
• Beth Zelnick Kaufman (person) — Corporate Secretary

FAQ

Risk Factors

• Nasdaq Listing Compliance [high — regulatory]: The company is seeking approval to remove the exchange cap under Nasdaq Rule 5635(a). Failure to secure this approval could lead to non-compliance with Nasdaq listing requirements, potentially resulting in delisting. This is critical for maintaining market access and investor confidence.
• Dilution from Incentive Plan [medium — financial]: The proposed amendment to the 2019 Omnibus Stock Incentive Plan seeks to increase authorized shares by 4,312,000. This represents a potential dilution for existing common stockholders, impacting their ownership percentage and potentially the value of their shares.
• Preferred Stockholder Voting Rights [medium — legal]: An amendment to the Certificate of Incorporation is proposed to grant preferred stockholders voting rights on certain charter amendments. This could alter the balance of voting power and influence on future corporate decisions, potentially impacting common stockholder interests.

Industry Context

CorMedix operates in the biopharmaceutical sector, focusing on developing and commercializing treatments for rare diseases. This industry is characterized by high R&D costs, long development cycles, significant regulatory hurdles (FDA approval), and intense competition from both established pharmaceutical giants and emerging biotech firms. Success often hinges on clinical trial outcomes, intellectual property protection, and effective market access strategies.

Regulatory Implications

The company faces significant regulatory scrutiny, particularly concerning the approval and commercialization of its drug candidates. Compliance with FDA regulations and Nasdaq listing rules are paramount. The proposed exchange cap removal and incentive plan amendments are subject to shareholder approval, which is a form of corporate governance regulation.

What Investors Should Do

1. Review the five proposals carefully, paying attention to the potential dilution from the incentive plan increase (4,312,000 shares) and the implications of granting voting rights to preferred stockholders.
2. Understand the voting power associated with different share classes: 78,340,257 common shares, 89,623 Series E preferred shares (709,299 votes), and 2,000 Series C-3 preferred shares (2,000 votes).
3. Assess the strategic importance of the Exchange Cap Removal proposal for CorMedix's future business development and Nasdaq listing compliance.
4. Vote by the deadline to ensure your voice is heard on these critical corporate governance and capital structure matters.

Key Dates

• 2025-11-10: Special Meeting of Stockholders — Shareholders will vote on critical proposals including exchange cap removal, incentive plan amendments, and charter changes. The outcome will shape the company's governance and capital structure.
• 2025-09-23: Record Date — Determined the stockholders (78,340,257 common shares, 89,623 Series E preferred shares, 2,000 Series C-3 preferred shares) eligible to vote at the Special Meeting.

Glossary

DEF 14A

A proxy statement filed with the SEC by publicly traded companies. It provides shareholders with information about matters to be voted on at a shareholder meeting. (This document details the proposals CorMedix Inc. is asking shareholders to approve at their Special Meeting.)

Exchange Cap Removal (Nasdaq Rule 5635(a))

A Nasdaq rule that typically requires shareholder approval for the issuance of securities in connection with the acquisition of the assets or businesses of another company if the stock issued exceeds 20% of the outstanding common stock or voting power. (CorMedix needs shareholder approval to remove this cap, likely to facilitate a transaction without triggering this requirement.)

Omnibus Stock Incentive Plan

A plan that allows a company to grant various types of equity-based compensation, such as stock options, restricted stock, and stock appreciation rights, to employees and directors. (CorMedix is seeking to increase the number of shares available under its existing plan, which could lead to future equity awards and potential dilution.)

Certificate of Incorporation

The foundational legal document that establishes a corporation and outlines its basic structure, purpose, and powers. (CorMedix is proposing amendments to this document, which requires shareholder approval and can significantly alter corporate governance.)

Record Date

A specific date set by a company to determine which shareholders are eligible to receive dividends, vote on corporate matters, or exercise other shareholder rights. (Establishes the pool of shareholders entitled to vote at the November 10, 2025, Special Meeting.)

Year-Over-Year Comparison

This filing is a proxy statement for a special meeting, not an annual report comparing year-over-year financial performance. Therefore, direct comparisons of revenue growth, margin changes, or updated risk factors from a previous annual filing are not available within this document. The focus is on specific proposals requiring shareholder approval rather than a comprehensive financial review.

Filing Documents

• ea0261891-01.htm (DEF 14A) — 692KB
• tproxy_001.jpg (GRAPHIC) — 1128KB
• tproxy_002.jpg (GRAPHIC) — 986KB
• 0001213900-25-101906.txt ( ) — 3607KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT   29 STOCKHOLDER COMMUNICATIONS   31 DEADLINE FOR STOCKHOLDER PROPOSALS FOR 2026 ANNUAL MEETING   31 DELIVERY OF DOCUMENTS TO STOCKHOLDERS SHARING AN ADDRESS   32 WHERE YOU CAN FIND ADDITIONAL INFORMATION   32 INSTRUCTIONS TO CORMEDIX INC. 2025 VIRTUAL SPECIAL MEETING   32 i Table of Contents CAUTIONARY NOTICE REGARDING FORWARD-LOOKING STATEMENTS Certain statements in this proxy statement for CorMedix Inc.’s (the “Company”, “CorMedix”, “we”, “our”) 2025 Special Meeting of Stockholders (the “Special Meeting”), including the documents that we incorporate by reference, contain “forward -looking statements” that involve risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward -looking statements. The statements contained in this proxy statement that are not purely historical are forward -looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward -looking statements are often identified by the use of words such as, but not limited to, “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “will,” “plan,” “project,” “seek,” “should,” “target,” “will,” “would,” and similar expressions or variations intended

View Full Filing

View this DEF 14A filing on SEC EDGAR